A five-year-old imaging company is betting that the next big shift in heart disease care will not come from a new drug or device, but from software that can read a routine CT scan and tell doctors exactly what is building up inside a patient’s coronary arteries. On September 2, 2026, Elucid, a Boston-area medical AI company, closed an oversubscribed $55 million Series D financing round, pushing its total capital raised to roughly $185 million since founding. The money is earmarked for commercial expansion of a platform that turns standard coronary CT angiography images into detailed 3D models of arterial plaque — work that until recently required invasive catheterization to approximate.
What the software actually does
Elucid’s flagship product, Plaque-IQ, received FDA clearance in 2024 and is built to quantify and classify the composition of plaque inside coronary arteries directly from CT angiogram images already being captured in many cardiology workups. Rather than simply flagging a blockage, the AI characterizes what the plaque is made of — distinguishing stable, calcified deposits from the softer, lipid-rich plaque that is more prone to rupture and trigger a heart attack. That distinction has historically been difficult to make without invasive imaging, and it matters clinically because two patients with similar-looking blockages on a standard scan can carry very different real-world risk.
A second tool waiting on FDA review
Behind Plaque-IQ, Elucid is developing BioIntegrated FFR-CT, an investigational tool that combines coronary anatomy, plaque biology and blood-flow physiology into a single read to assess whether a blockage is actually restricting blood flow enough to cause ischemia. The product is currently working through the FDA’s 510(k) clearance pathway. If cleared, it would give cardiologists a single, non-invasive report spanning structure, disease biology and function — three assessments that today are often split across separate invasive and non-invasive tests.
Coverage is already ahead of the hype
What sets Elucid apart from many AI diagnostic startups is that payers are already paying for it. By January 2026, more than 70% of covered Americans were enrolled in health plans that reimburse for Plaque-IQ, including coverage from Aetna, Humana, Cigna and UnitedHealthcare, alongside Medicare coverage through CMS. That kind of reimbursement traction is rare in an AI diagnostics field where many FDA-cleared tools still struggle to get paid for outside research settings, and it is a large part of why investors returned for a fourth round of funding.
Who backed the round
The Series D drew participation from IAG Capital Partners and Elevage Medical Technologies, a platform created by Patient Square Capital, along with a large, publicly traded medtech company that became Elucid’s fourth publicly traded strategic investor — a signal that established device makers see the plaque-characterization category as one worth aligning with rather than building from scratch. Elucid CEO Kelly Huang framed the company’s approach as a shift for cardiology akin to what precision oncology did for cancer treatment, telling reporters the company is applying AI to "integrate anatomy, biology and physiology to bring personalized treatment to coronary artery disease" instead of treating all blockages the same way.
The competitive backdrop
Elucid is not alone in trying to extract more diagnostic value out of the CT scans hospitals already perform. HeartFlow, a longer-established rival, offers its own FFR-CT analysis for assessing blood-flow-limiting blockages, and the two companies are increasingly positioned as competitors for the same cardiology contracts. The difference Elucid is emphasizing is breadth — pairing plaque composition with flow physiology in one platform — rather than a single functional readout. Heart disease remains the leading cause of death in the United States, and cardiologists have long lacked an easy, non-invasive way to see which plaques are dangerous rather than merely present, which is the gap both companies are racing to fill.
What comes next
The near-term test for Elucid is less about the technology working in a lab and more about whether hospital systems adopt it into everyday cardiology workflows now that the reimbursement groundwork is largely in place. A favorable 510(k) decision on BioIntegrated FFR-CT would give the company a combined structural-and-functional product to sell alongside Plaque-IQ, potentially consolidating tests that today are ordered separately. For patients, the practical promise is a scan they are often already getting — read with software that can say not just whether an artery is narrowed, but whether the material narrowing it is the kind likely to cause a heart attack. Whether that promise translates into better outcomes at scale, rather than just better pictures, is the question the next round of clinical follow-up data will need to answer.
